Olmutinib

Drug Profile

Olmutinib

Alternative Names: BI 1482694; EMSI; HM 61713B; HM61713; ZL-2303

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Boehringer Ingelheim; Hanmi Pharmaceutical; ZAI Lab
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer

Most Recent Events

  • 30 Sep 2016 Boehringer Ingelheim plans to return the development and global commercialisation rights of olmutinib to Hanmi Pharmaceuticals
  • 04 Aug 2016 Preclinical trials in Non-small cell lung cancer in China (PO)
  • 30 Jun 2016 Boehringer Ingelheim completes a phase I pharmacokinetics trial in Healthy male volunteers in Netherlands (PO) (NCT02722161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top